DK3285756T3 - Formuleringer af l-ornithinphenylacetat - Google Patents

Formuleringer af l-ornithinphenylacetat Download PDF

Info

Publication number
DK3285756T3
DK3285756T3 DK16783692.3T DK16783692T DK3285756T3 DK 3285756 T3 DK3285756 T3 DK 3285756T3 DK 16783692 T DK16783692 T DK 16783692T DK 3285756 T3 DK3285756 T3 DK 3285756T3
Authority
DK
Denmark
Prior art keywords
formulations
phenyl acetate
ornithine phenyl
ornithine
acetate
Prior art date
Application number
DK16783692.3T
Other languages
English (en)
Inventor
Laurene Wang
Kenneth Ruettimann
Mark Coffin
James Bernstein
Gary Goodson
Original Assignee
Ocera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ocera Therapeutics Inc filed Critical Ocera Therapeutics Inc
Application granted granted Critical
Publication of DK3285756T3 publication Critical patent/DK3285756T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK16783692.3T 2015-04-20 2016-04-19 Formuleringer af l-ornithinphenylacetat DK3285756T3 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562150238P 2015-04-20 2015-04-20
US201562150676P 2015-04-21 2015-04-21
US201562211619P 2015-08-28 2015-08-28
US201562255300P 2015-11-13 2015-11-13
US201662276754P 2016-01-08 2016-01-08
PCT/US2016/028298 WO2016172112A1 (en) 2015-04-20 2016-04-19 Formulations of l-ornithine phenylacetate

Publications (1)

Publication Number Publication Date
DK3285756T3 true DK3285756T3 (da) 2023-05-08

Family

ID=57144228

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16783692.3T DK3285756T3 (da) 2015-04-20 2016-04-19 Formuleringer af l-ornithinphenylacetat

Country Status (13)

Country Link
US (2) US20160338982A1 (da)
EP (2) EP4205735A1 (da)
JP (2) JP2018513171A (da)
KR (1) KR20180006904A (da)
CN (2) CN113599350A (da)
AU (2) AU2016252382A1 (da)
CA (1) CA2983146C (da)
DK (1) DK3285756T3 (da)
ES (1) ES2944311T3 (da)
HK (1) HK1251149A1 (da)
MX (2) MX391167B (da)
RU (1) RU2755904C2 (da)
WO (1) WO2016172112A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2448549T3 (es) 2004-11-26 2014-03-14 Ucl Business Plc Composiciones que comprenden ornitina y fenilacetato o fenilbutirato para tratar encefalopatía hepática
ES2652187T3 (es) 2009-04-03 2018-01-31 Ocera Therapeutics, Inc. Fenilacetato de l-ornitina y métodos para elaborar el mismo
EP2440200B8 (en) 2009-06-08 2014-10-15 UCL Business PLC Treatment of portal hypertension using l-ornithine phenylacetate
KR102487376B1 (ko) 2014-11-24 2023-01-10 유씨엘 비즈니스 리미티드 암모니아-저감 치료를 이용한 간성상세포 활성화와 연관된 질병의 치료
JP6990170B2 (ja) 2015-08-18 2022-01-12 オセラ セラピューティクス, インコーポレイテッド L-オルニチンをフェニルアセテートおよびフェニルブチレートのうちの少なくとも1つと組み合わせて用いる筋肉喪失の治療および予防
SG11201802987UA (en) * 2015-11-13 2018-05-30 Ocera Therapeutics Inc Formulation of l-ornithine phenylacetate
US11219611B2 (en) 2015-11-13 2022-01-11 Ocera Therapeutics, Inc. Formulations of L-ornithine phenylacetate
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
CN110740988A (zh) 2017-05-11 2020-01-31 欧塞拉治疗有限公司 制备l-鸟氨酸苯乙酸盐的方法
SG11202001142VA (en) 2017-08-14 2020-03-30 Axcella Health Inc Amino acid compositions for the treatment of liver disease
US10596136B2 (en) 2018-06-20 2020-03-24 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
AU2020270106A1 (en) 2019-05-09 2021-11-18 Ocera Therapeutics, Inc. Methods of assessing and treating hepatic encephalopathy
CN114786662A (zh) * 2019-10-16 2022-07-22 欧塞拉治疗有限公司 鸟氨酸苯乙酸盐用于治疗高氨血症的剂量和用途
WO2021152587A1 (en) 2020-01-30 2021-08-05 Yeda Research And Development Co. Ltd. Treating acute liver disease with tlr-mik inhibitors
WO2024261477A1 (en) 2023-06-20 2024-12-26 Yaqrit Limited Combination of tlr4 antagonist, ornithine and phenylacetate or phenylbutyrate

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
IL116674A (en) * 1995-01-09 2003-05-29 Mendell Co Inc Edward Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof
ES2448549T3 (es) 2004-11-26 2014-03-14 Ucl Business Plc Composiciones que comprenden ornitina y fenilacetato o fenilbutirato para tratar encefalopatía hepática
ES2652187T3 (es) * 2009-04-03 2018-01-31 Ocera Therapeutics, Inc. Fenilacetato de l-ornitina y métodos para elaborar el mismo
AU2015221466B2 (en) * 2009-04-03 2017-02-02 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
AU2014250643B2 (en) * 2009-06-08 2016-07-14 Ocera Therapeutics, Inc. Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate
EP2440200B8 (en) * 2009-06-08 2014-10-15 UCL Business PLC Treatment of portal hypertension using l-ornithine phenylacetate
EP2625162B1 (en) * 2010-10-06 2019-03-13 Ocera Therapeutics, Inc. Methods of making l-ornithine phenyl acetate

Also Published As

Publication number Publication date
JP2018513171A (ja) 2018-05-24
CN113599350A (zh) 2021-11-05
EP4205735A1 (en) 2023-07-05
JP2022101549A (ja) 2022-07-06
ES2944311T3 (es) 2023-06-20
MX2022003855A (es) 2023-03-02
EP3285756A1 (en) 2018-02-28
KR20180006904A (ko) 2018-01-19
US20220184014A1 (en) 2022-06-16
MX391167B (es) 2025-03-11
US20160338982A1 (en) 2016-11-24
CA2983146A1 (en) 2016-10-27
EP3285756B1 (en) 2023-02-22
WO2016172112A1 (en) 2016-10-27
CN107708684A (zh) 2018-02-16
MX2017013170A (es) 2018-04-11
AU2021200740A1 (en) 2021-03-04
CA2983146C (en) 2023-09-12
EP3285756A4 (en) 2019-01-23
RU2755904C2 (ru) 2021-09-22
RU2017137643A3 (da) 2019-09-17
RU2017137643A (ru) 2019-05-20
AU2016252382A1 (en) 2017-11-02
HK1251149A1 (zh) 2019-01-25

Similar Documents

Publication Publication Date Title
DK3509581T3 (da) Formuleringer af (r)-2-amino-3-phenylpropylcarbamat
DK3137169T3 (da) Hæmmere af lysin-specifik demethylase-1
DK3626081T3 (da) Pasteuriseret akkermansia til fremme af vægttab
DK3317400T3 (da) Fremgangsmåde til kryokonservering af tumorinfiltrerende lymfocytter
SI3769781T1 (sl) Stabilna formulacija proti-IFNAR1
DK3102576T3 (da) Dihydropyrrolopyridininhibitorer af ror-gamma
DK3185853T3 (da) Inhalerbare pulverformuleringer af alginatoligomerer
DK3164380T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3180331T3 (da) Polymorfer af selinexor
DK3259349T3 (da) Dehydrogenase-katalyseret fremstilling af FDCA
DK3220891T3 (da) Sublingual formulering af riluzol
EP3273950A4 (en) ADJUVANE COMPOSITIONS AND RELATED METHODS
DK3250182T3 (da) Dispergible sammensætninger
DK3798222T3 (da) Krystallinsk form af den frie base af lorlatinib
DK3512857T3 (da) Spiro-bicykliske inhibitorer af menin-mll-interaktion
MA42692A (fr) Compositions biopharmaceutiques
DK3334726T3 (da) Plinabulinsammensætninger
DK3474822T3 (da) Formuleringer af brincidofovir
EP3364945C0 (en) SOLID FORMULATION
DK3943070T3 (da) Langtidsvirkende formuleringer af bedaquilin
DK3280408T3 (da) Fremgangsmåde til fremstilling af dicycloplatin
DK3307267T3 (da) Behandling af multipel sklerose
DK3418273T3 (da) Derivater af flavagliner
DK3697418T3 (da) Forbedrede formuleringer af bromocriptin
DK3204352T3 (da) Hæmmere af lysin-gingipain